{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:34:41Z","timestamp":1781886881629,"version":"3.54.5"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013362","name":"Cancer Research Foundation Switzerland","doi-asserted-by":"publisher","award":["KFS-5270-02-2021"],"award-info":[{"award-number":["KFS-5270-02-2021"]}],"id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019688","name":"Functional Genomics Center Zurich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003006","name":"Eidgen\u00f6ssische Technische Hochschule Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.canlet.2026.218300","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:55:41Z","timestamp":1770191741000},"page":"218300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting ATR signaling in sarcoma with homologous recombination deficiency"],"prefix":"10.1016","volume":"642","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9603-9257","authenticated-orcid":false,"given":"L.","family":"Planas-Paz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zehnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Desboeufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kollar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schneebeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0070-3775","authenticated-orcid":false,"given":"R.","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8454-267X","authenticated-orcid":false,"given":"M.P.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9621-8511","authenticated-orcid":false,"given":"C.","family":"Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218300_bib1","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218300_bib2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218300_bib3","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218300_bib4","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib5","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218300_bib6","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II Study of maintenance Rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib7","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib9","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216863","article-title":"Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma","volume":"15","author":"Planas-Paz","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.canlet.2026.218300_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jnci\/djab169","article-title":"Homologous recombination deficiency alterations in colorectal cancer: clinical, molecular, and prognostic implications","volume":"114","author":"Moretto","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2026.218300_bib11","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s00432-021-03781-6","article-title":"The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors","volume":"148","author":"Kim","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib12","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.trecan.2021.08.007","article-title":"Tackling PARP inhibitor resistance","volume":"7","author":"Fugger","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2026.218300_bib13","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1038\/s41388-024-03105-1","article-title":"GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway","volume":"43","author":"Ikeuchi","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218300_bib14","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218300_bib15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218300_bib16","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218300_bib17","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous Recombination Deficiency (HRD) Score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218300_bib18","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218300_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41698-022-00339-8","article-title":"Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer","volume":"6","author":"Perez-Villatoro","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218300_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41698-022-00276-6","article-title":"Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)","volume":"6","author":"Rempel","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib22","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib23","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.omtn.2021.10.014","article-title":"A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level","volume":"26","author":"Zhuang","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.canlet.2026.218300_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103135","article-title":"Discovering a qualitative transcriptional signature of homologous recombination defectiveness for prostate cancer","volume":"24","author":"Li","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.canlet.2026.218300_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41523-024-00671-1","article-title":"Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer","volume":"10","author":"Pan","year":"2024","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.canlet.2026.218300_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-023-00368-x","article-title":"Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration","volume":"7","author":"Tsang","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/gcc.22703","article-title":"CINSARC signature as a prognostic marker for clinical outcome in sarcomas and beyond","volume":"58","author":"Chibon","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.canlet.2026.218300_bib28","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1158\/0008-5472.CAN-20-0512","article-title":"A global and integrated analysis of CINSARC-Associated genetic defects","volume":"80","author":"Lesluyes","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218300_bib29","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1038\/s41598-017-05726-x","article-title":"The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms","volume":"7","author":"Lesluyes","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218300_bib30","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.trecan.2021.06.002","article-title":"Targeting the replication stress response through synthetic lethal strategies in cancer medicine","volume":"7","author":"Ngoi","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2026.218300_bib31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218300_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.canlet.2026.218300_bib33","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","article-title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Matsuoka","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218300_bib34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib35","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218300_bib36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218300_bib37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s13577-022-00818-x","article-title":"Establishment, characterization and functional testing of two novel ex vivo extraskeletal myxoid chondrosarcoma (EMC) cell models","volume":"36","author":"Bangerter","year":"2023","journal-title":"Hum. Cell"},{"key":"10.1016\/j.canlet.2026.218300_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2022.100039","article-title":"Addressing modern diagnostic pathology for patient-derived soft tissue sarcosphere models in the era of functional precision oncology","volume":"103","author":"Chen","year":"2023","journal-title":"Lab. Invest."},{"key":"10.1016\/j.canlet.2026.218300_bib39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.canlet.2026.218300_bib40","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1073\/pnas.082099299","article-title":"Diagnosis of multiple cancer types by shrunken centroids of gene expression","volume":"99","author":"Tibshirani","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218300_bib41","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/annonc\/mdy194","article-title":"Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas","volume":"29","author":"Le Guellec","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib42","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: a curated database of somatic variants and clinical data for cancer","volume":"52","author":"Sondka","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2026.218300_bib43","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinform."},{"key":"10.1016\/j.canlet.2026.218300_bib44","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","article-title":"A new wave of innovations within the DNA damage response","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218300_bib45","doi-asserted-by":"crossref","first-page":"28707","DOI":"10.1074\/jbc.M111.248914","article-title":"Thr-1989 phosphorylation is a marker of active ataxia telangiectasia-mutated and Rad3-related (ATR) kinase","volume":"286","author":"Nam","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218300_bib46","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molcel.2011.06.019","article-title":"ATR autophosphorylation as a molecular switch for checkpoint activation","volume":"43","author":"Liu","year":"2011","journal-title":"Mol Cell"},{"key":"10.1016\/j.canlet.2026.218300_bib47","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1128\/MCB.21.13.4129-4139.2001","article-title":"ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1","volume":"21","author":"Zhao","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218300_bib48","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","article-title":"Biomarkers associating with PARP Inhibitor Benefit in prostate cancer in the TOPARP-B trial","volume":"11","author":"Carreira","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218300_bib49","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonzalez-Martin","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218300_bib51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejca.2021.09.028","article-title":"Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1\/2 mutation","volume":"159","author":"Patsouris","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218300_bib52","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamaoncol.2021.0006","article-title":"Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants: findings from 2 phase 2 nonrandomized clinical trials","volume":"7","author":"Javle","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00402-024-05711-w","article-title":"Precision medicine in diagnosis, prognosis, and disease monitoring of bone and soft tissue sarcomas using liquid biopsy: a systematic review","volume":"145","author":"Smolle","year":"2025","journal-title":"Arch. Orthop. Trauma Surg."},{"key":"10.1016\/j.canlet.2026.218300_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115169","article-title":"Homologous recombination deficiency in ovarian cancer: global expert consensus on testing and a comparison of companion diagnostics","volume":"215","author":"Quesada","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218300_bib55","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/cam4.5015","article-title":"CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: results from the ISG-STS 1001 study","volume":"12","author":"Frezza","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2026.218300_bib56","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218300_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cells11121889","article-title":"The influence of PARP, ATR, CHK1 inhibitors on premature mitotic entry and genomic instability in high-grade serous BRCA(MUT) and BRCA(WT) ovarian cancer cells","volume":"11","author":"Gralewska","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218300_bib58","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.bcp.2012.02.026","article-title":"Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation","volume":"83","author":"Forrest","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218300_bib59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s44320-025-00085-6","article-title":"Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response","volume":"21","author":"Hofer","year":"2025","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.canlet.2026.218300_bib60","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41586-023-06506-6","article-title":"Poltheta is phosphorylated by PLK1 to repair double-strand breaks in mitosis","volume":"621","author":"Gelot","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218300_bib61","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","article-title":"A first-in-class Polymerase Theta Inhibitor selectively targets homologous-recombination-deficient Tumors","volume":"2","author":"Zhou","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2026.218300_bib62","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","article-title":"Poltheta inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance","volume":"12","author":"Zatreanu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218300_bib63","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920956900","article-title":"Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma","volume":"12","author":"Li","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218300_bib64","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41580-020-0257-5","article-title":"The plasticity of DNA replication forks in response to clinically relevant genotoxic stress","volume":"21","author":"Berti","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218300_bib65","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.tig.2024.04.013","article-title":"Single-stranded DNA) gaps in understanding BRCAness","volume":"40","author":"Schreuder","year":"2024","journal-title":"Trends Genet."},{"key":"10.1016\/j.canlet.2026.218300_bib66","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","article-title":"Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma","volume":"168","author":"Harold","year":"2023","journal-title":"Gynecol. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:08:23Z","timestamp":1772075303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":66,"alternative-id":["S0304383526000637"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218300","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting ATR signaling in sarcoma with homologous recombination deficiency","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218300"}}